Needham & Company
View Older Stories
-
Pre-Open Stock Movers 09/12: (FOMX) (TLRY) (NLSN) Higher; (VTL) (SNAP) (MU) Lower (more...)
-
Pre-Open Movers 08/28: (IXYS) (KITE) (JUNO) Higher; (TRV) (MET) (ALL) Lower (more...)
-
Sarepta Therapeutics (SRPT) PT Lowered to $78 at Needham & Company; PRV Sale Closes Funding Gap
-
Pre-Open Stock Movers 02/08: (MYGN) (COHR) (MCHP) Higher; (GALE) (USNA) (EYES) Lower (more...)
-
Needham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q
-
Needham & Company Downgrades Gilead Sciences (GILD) to Hold
-
Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
-
Pre-Open Stock Movers 05/01: (ENOC) (SYT) (OCN) Higher; (LNKD) (PODD) (CTCT) Lower (more...)
-
Gilead Sciences (GILD) Estimates Trimmed at Needham & Company Post Q4; 'Buy' Maintained
-
Notable Analyst Rating Changes 1/6: (ORCL) (FDX) (LOCO) Upgraded; (INFN) (GE) (KORS) Downgraded
-
Market Wrap: Activist Zeroes in on Manitowoc; Shake Shack to go Public; Associated Estates Eyes Sale
-
Notable Analyst Rating Changes 12/29: (MWE) (GILD) (IPHI) Upgraded; SWKS) (XGTI) (AMBA) Downgraded
-
Pre-Open Stock Movers 12/29: (LIVE) (MTW) (RXDX) Higher; (NBG) (AMBA) (GPRO) Lower (more...)
-
Gilead Sciences (GILD) PT Raised to $120 at Needham & Company
-
Gilead Sciences (GILD) Target Lifted at Needham & Company Post Q4
-
Notable Analyst Rating Changes 01/08: (RAD) (PNRA) (FLIR) Upgraded; (AMBA) (TWTR) (TCS) Downgraded
-
Pre-Open Stock Movers 12/9: (SYY) (GIVN) (UQM) Higher; (NIHD) (PLUG) (EZPW) Lower (more...)
-
Gilead Sciences (GILD) Target Price Upped to $85 at Needham & Company Post Q3
-
Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT) (CKSW) Lower (more...)
-
Gilead Sciences (GILD) Numbers Raised after Solid Qtr - Needham & Company
-
Needham & Company Boosts PT on Gilead Sciences (GILD) to $62
-
StreetInsider.com Pre-Open Movers 03/25: (APOL) (DG) (DELL) Higher; (OTT) (IDIX) (BBRY) Lower (more...)
-
StreetInsider.com Pre-Open Movers 11/12: (TIE) (JEF) (GILD) Higher; (CLVS) (STSI) (GRMN) Lower (more...)
-
Analysts Remain Bullish on Gilead (GILD) as Antiviral Franchise Solid
-
Notable 52-Week Highs and Lows of the Day 10/01: (KFT) (THC) (GILD) High; (HUSA) (ATML) (JAKK) Low
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Raising PT and Estimates
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Q2 Beats; Management Maps Out Phase 3 GS-7977 Plans
-
Needham & Company Maintains a 'Buy' on Gilead Sciences (GILD); Q2 Preview; Quad Pill Update
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Raising Numbers on Recent Progress in HCV
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD) on Positive Interim Data from GS7977 Trials
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Update Frtom 2012 CROI Meeting
-
Notable Analyst Rating Changes 02/21: (DANG) (FRO) (BRCM) Upgraded; (UA) (GILD) (CTRP) Downgraded
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Mixed Q4; Encouraging Update from GS7977 Program in HCV
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); 2012 Preview
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Maintains a 'Buy' on Gilead Sciences (GILD); Believe Stock is Underappreciated
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); 2Q11 Results Slightly Above Expectations; Upcoming 3Q11 Milestones in HIV are Key
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); 1Q11 Results Disappoint, but 2011 Guidance Maintained; HIV/HCV Pipeline Progress May Be Catalyst
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); 2010 Results In-Line, but 2011 Revenue Guidance Lower than Expected
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD)
-
Notable Analyst Rating Changes 11/16: CAT, CREE, S, BRCD Upgraded; NLST, BUCY, PWRD, JOYG Downgraded
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); 2Q10 Results a Disappointment. We Still Favor Stock in Long-Term
-
Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Updating Estimates Ahead of 2Q10 Earnings
-
Unusual 11 Mid-Day Movers 4/21: DEAR, CYBS, CTT, RPTP, OBCI Higher; VITC, CSIQ, RDCM, GTF Lower
-
Notable Analyst Rating Changes 04/21: RPM, GET, VMW, MANH Upgraded; VITC, GILD, SNV, WFT Downgraded
-
Morning Movers 4/21: DEAR, BNVI, OBCI, CYBS, AKRX, MANH Higher; VITC, TSFG, CSIQ, GILD, SNV Lower
-
Needham & Company Reiterates a 'Strong Buy' on Gilead Sciences (GILD)
-
Needham & Co Reiterates a 'Buy' Rating on Gilead Sciences (GILD); Raises PT & Estimates
-
Notable Analyst Rating Changes 11/12: BBBY, PAG, ROK Upgraded; EGLE, FMCN, BRCM Downgraded
-
Needham & Co Initiates Coverage on Gilead Sciences (GILD), Represents Core Holding